Nusbaum Jeffrey D, Smirniotopoulos John, Wright Henry C, Dash Chiranjeev, Parpia Tarina, Shechtel Joanna, Chang Yaojen, Loffredo Christopher, Shetty Kirti
*Transplant Institute, Georgetown University Hospital †Lombardi Comprehensive Cancer Center, Georgetown University Medical Center ‡Division of Gastroenterology and Hepatology, Johns Hopkins Medical Institutions, Washington, DC.
J Clin Gastroenterol. 2015 Nov-Dec;49(10):e91-5. doi: 10.1097/MCG.0000000000000306.
Hepatocellular carcinoma (HCC) surveillance in patients with cirrhosis is aimed at early detection so that effective therapeutic options may be offered. We undertook this study to assess the patterns of surveillance that had been offered to HCC patients evaluated at our center, and the effect of these strategies on outcome.
Consecutive patients, age 18 years and older, diagnosed with HCC between December 2007 and December 2012 were identified. Surveillance was defined as α-fetoprotein measurement and/or imaging examination in the 12 months before HCC diagnosis. Logistic regression and survival analysis models were utilized to investigate the association of surveillance with patient characteristics and survival.
A total of 305 patients with HCC and a background of cirrhosis were analyzed. HCC was detected by surveillance in 131 patients (43%). Of those who underwent surveillance, 92% were diagnosed with early-stage cancer (stages I and II) compared with 62% of those who did not undergo surveillance (P<0.001). The rate of surgical therapy (hepatic resection and liver transplantation) was almost doubled in the surveillance group (61% vs. 33%, P<0.05). At median follow-up of 27.3 months, overall survival was high at 55% and surveillance was significantly associated with longer survival (P=0.006).
At our center, surveillance efficacy for HCC detection was notably higher than earlier reported.
Patients who underwent surveillance were more likely to have their tumors detected at an early stage, to qualify for surgical therapy, and to have improved survival.
对肝硬化患者进行肝细胞癌(HCC)监测旨在早期发现,以便能够提供有效的治疗选择。我们开展这项研究以评估在我们中心接受评估的HCC患者所采用的监测模式,以及这些策略对预后的影响。
确定2007年12月至2012年12月期间连续诊断为HCC的18岁及以上患者。监测定义为在HCC诊断前12个月内进行甲胎蛋白测量和/或影像学检查。采用逻辑回归和生存分析模型来研究监测与患者特征及生存之间的关联。
共分析了305例有肝硬化背景的HCC患者。通过监测发现HCC的患者有131例(43%)。在接受监测的患者中,92%被诊断为早期癌症(I期和II期),而未接受监测的患者中这一比例为62%(P<0.001)。监测组的手术治疗率(肝切除和肝移植)几乎翻倍(61%对33%,P<0.05)。在中位随访27.3个月时,总生存率较高,为55%,且监测与更长的生存期显著相关(P=0.006)。
在我们中心,HCC检测的监测效果明显高于早期报道。
接受监测的患者更有可能在早期发现肿瘤,有资格接受手术治疗,并改善生存情况。